BridgeBio Pharma (BBIO) Stock Forecast & Price Target

→ Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad)

$25.33

+0.13 (+0.52%)

(As of 06/28/2024 08:55 PM ET)

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Consensus Price Target

$47.21
86.40% Upside

High Forecast	$70.00
Average Forecast	$47.21
Low Forecast	$33.00

Type	Current Forecast 7/2/23 to 7/1/24	1 Month Ago 6/2/23 to 6/1/24	3 Months Ago 4/3/23 to 4/2/24	1 Year Ago 7/2/22 to 7/2/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$47.21	$47.62	$45.62	$26.63
Forecasted Upside	86.40% Upside	54.04% Upside	55.30% Upside	73.53% Upside

Ad Porter & Company

Young billionaire opens the door for millions of Americans

You can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. households in the months and years to come. And you can do this whether you’re rich or poor… There are no special income requirements.

Anyone can do this.

BBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BridgeBio Pharma Stock vs. The Competition

Type	BridgeBio Pharma	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.71	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	86.40% Upside	804.36% Upside	11.52% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$50.00 ➝ $42.00	+77.51%
6/20/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $43.00	+55.74%
5/28/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$70.00 ➝ $70.00	+152.34%
5/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$51.00 ➝ $47.00	+68.22%
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00	+75.44%
3/21/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00	+57.18%
Trump’s arrest is phase one (Ad) When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late.
3/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$35.00 ➝ $45.00	+58.28%
3/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$60.00 ➝ $53.00	+63.81%
2/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$42.00 ➝ $46.00	+34.58%
1/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$37.00	+2.52%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$58.00	+72.57%
7/18/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$29.00 ➝ $50.00	+56.05%
7/18/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$32.00 ➝ $42.00	+31.09%
7/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00 ➝ $33.00	+3.00%
4/13/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$25.00 ➝ $27.00	+77.87%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
1/23/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform	$23.00 ➝ $19.00	+123.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:44 AM ET.

BBIO Forecast - Frequently Asked Questions

What is BridgeBio Pharma's stock forecast and purchase recommendation?: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for BridgeBio Pharma is $47.21, with a high forecast of $70.00 and a low forecast of $33.00. The consensus rating for BridgeBio Pharma stock is Moderate Buy based on the current 2 hold ratings, 10 buy ratings and 1 strong buy rating for BBIO. Learn more on BBIO's analyst rating history.
Do Wall Street analysts like BridgeBio Pharma more than its competitors?: Analysts like BridgeBio Pharma more than other "medical" companies. The consensus rating score for BridgeBio Pharma is 2.92 while the average consensus rating score for "medical" companies is 2.70. Learn more on how BBIO compares to other companies.
Is BridgeBio Pharma being upgraded by Wall Street analysts?: Over the previous 90 days, BridgeBio Pharma's stock had 1 upgrade by analysts.

Does BridgeBio Pharma's stock price have much upside?: According to analysts, BridgeBio Pharma's stock has a predicted upside of 55.55% based on their 12-month stock forecasts.
What analysts cover BridgeBio Pharma?: BridgeBio Pharma has been rated by research analysts at Bank of America, Cantor Fitzgerald, Evercore ISI, HC Wainwright, and UBS Group in the past 90 days.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:BBIO) was last updated on 7/1/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

Consensus Rating

Consensus Price Target

BBIO Analyst Recommendations By Month

BBIO Price Targets by Month

BridgeBio Pharma Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

BBIO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

Consensus Rating

Consensus Price Target

BBIO Analyst Recommendations By Month

BBIO Price Targets by Month

BridgeBio Pharma Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

BBIO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools